New Peer-Reviewed Research Demonstrates Effectiveness of Paradigm Health Study Conduct Products

New peer-reviewed research demonstrates the feasibility and effectiveness of Paradigm Health's EHR-integrated eSource platform to support late-stage clinical research in community oncology settings.
Seeking Alpha

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), ...
Fox News

Ozempic could help reduce Alzheimer’s risk for some, study suggests: ‘Shifting the paradigm’

Semaglutide medications — such as Ozempic, the popular diabetes drug — have been linked to a reduced risk of Alzheimer’s disease for certain groups. A new study, which was led by researchers at Case ...
Healio

VIDEO: Study enrollment underway that could ‘change the treatment paradigm for myeloma’

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The main focus right now in the myeloma ...
Seeking Alpha

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower ...
ascopubs.org

The crossover of the bevacizumab and panitumumab survival curves in the PARADIGM study: A clue to time-related effects of bevacizumab on the risk of tumor progression.

Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: Results from the UNICORN trial by GONO. Outcomes of ...